1α,25-dihydroxyvitamin D3 increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human bone cells

Yanhong Wu, James D. Haugen, Alan R. Zinsmeister, Rajiv Kumar

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

To determine whether the inhibition of human osteoblast growth mediated by 1α,25-dihydroxyvitamin D3 (1α,25(OH)D3) occurs as a result of changes in transforming growth factor (TGF) and TGF receptor synthesis, we examined the effects of 1α,25(OH)2D3 on the synthesis of TGFβ and TGF-β receptors. Treatment with 1α,25(OH)2D3, but not vehicle, increased TGF-β2 concentrations in human osteoblast cell supernantants in a dose- and time-dependent manner. The increase in TGF-β2 concentrations was associated with an inhibition of osteoblast cell growth; antibodies directed against transforming growth factor β partially blocked the inhibition of cellular growth mediated by 1α,25(OH)2D3. TGF-β2 gene transcription and TGF-β2 mRNA concentrations were increased in 1α,25(OH)D3 but not in vehicle-treated cells. 1α,25(OH)2D3 increased TGF-β type I and type II receptor mRNA levels in osteoblasts. Increased expression of TGF-β2 and TGF-β receptors by 1α,25(OH)2D3 might account for the inhibition of human osteoblast growth seen following 1α,25(OH)2D3 treatment.

Original languageEnglish (US)
Pages (from-to)734-739
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume239
Issue number3
DOIs
StatePublished - Oct 29 1997

Fingerprint

Growth Factor Receptors
Calcitriol
Transforming Growth Factors
Bone
Bone and Bones
Osteoblasts
Growth
Messenger RNA
Cell growth
Transcription
Genes
Cells

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

1α,25-dihydroxyvitamin D3 increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human bone cells. / Wu, Yanhong; Haugen, James D.; Zinsmeister, Alan R.; Kumar, Rajiv.

In: Biochemical and Biophysical Research Communications, Vol. 239, No. 3, 29.10.1997, p. 734-739.

Research output: Contribution to journalArticle

@article{245ebc5e7eec406f81b4085a1e8c2dde,
title = "1α,25-dihydroxyvitamin D3 increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human bone cells",
abstract = "To determine whether the inhibition of human osteoblast growth mediated by 1α,25-dihydroxyvitamin D3 (1α,25(OH)D3) occurs as a result of changes in transforming growth factor (TGF) and TGF receptor synthesis, we examined the effects of 1α,25(OH)2D3 on the synthesis of TGFβ and TGF-β receptors. Treatment with 1α,25(OH)2D3, but not vehicle, increased TGF-β2 concentrations in human osteoblast cell supernantants in a dose- and time-dependent manner. The increase in TGF-β2 concentrations was associated with an inhibition of osteoblast cell growth; antibodies directed against transforming growth factor β partially blocked the inhibition of cellular growth mediated by 1α,25(OH)2D3. TGF-β2 gene transcription and TGF-β2 mRNA concentrations were increased in 1α,25(OH)D3 but not in vehicle-treated cells. 1α,25(OH)2D3 increased TGF-β type I and type II receptor mRNA levels in osteoblasts. Increased expression of TGF-β2 and TGF-β receptors by 1α,25(OH)2D3 might account for the inhibition of human osteoblast growth seen following 1α,25(OH)2D3 treatment.",
author = "Yanhong Wu and Haugen, {James D.} and Zinsmeister, {Alan R.} and Rajiv Kumar",
year = "1997",
month = "10",
day = "29",
doi = "10.1006/bbrc.1997.7544",
language = "English (US)",
volume = "239",
pages = "734--739",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - 1α,25-dihydroxyvitamin D3 increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human bone cells

AU - Wu, Yanhong

AU - Haugen, James D.

AU - Zinsmeister, Alan R.

AU - Kumar, Rajiv

PY - 1997/10/29

Y1 - 1997/10/29

N2 - To determine whether the inhibition of human osteoblast growth mediated by 1α,25-dihydroxyvitamin D3 (1α,25(OH)D3) occurs as a result of changes in transforming growth factor (TGF) and TGF receptor synthesis, we examined the effects of 1α,25(OH)2D3 on the synthesis of TGFβ and TGF-β receptors. Treatment with 1α,25(OH)2D3, but not vehicle, increased TGF-β2 concentrations in human osteoblast cell supernantants in a dose- and time-dependent manner. The increase in TGF-β2 concentrations was associated with an inhibition of osteoblast cell growth; antibodies directed against transforming growth factor β partially blocked the inhibition of cellular growth mediated by 1α,25(OH)2D3. TGF-β2 gene transcription and TGF-β2 mRNA concentrations were increased in 1α,25(OH)D3 but not in vehicle-treated cells. 1α,25(OH)2D3 increased TGF-β type I and type II receptor mRNA levels in osteoblasts. Increased expression of TGF-β2 and TGF-β receptors by 1α,25(OH)2D3 might account for the inhibition of human osteoblast growth seen following 1α,25(OH)2D3 treatment.

AB - To determine whether the inhibition of human osteoblast growth mediated by 1α,25-dihydroxyvitamin D3 (1α,25(OH)D3) occurs as a result of changes in transforming growth factor (TGF) and TGF receptor synthesis, we examined the effects of 1α,25(OH)2D3 on the synthesis of TGFβ and TGF-β receptors. Treatment with 1α,25(OH)2D3, but not vehicle, increased TGF-β2 concentrations in human osteoblast cell supernantants in a dose- and time-dependent manner. The increase in TGF-β2 concentrations was associated with an inhibition of osteoblast cell growth; antibodies directed against transforming growth factor β partially blocked the inhibition of cellular growth mediated by 1α,25(OH)2D3. TGF-β2 gene transcription and TGF-β2 mRNA concentrations were increased in 1α,25(OH)D3 but not in vehicle-treated cells. 1α,25(OH)2D3 increased TGF-β type I and type II receptor mRNA levels in osteoblasts. Increased expression of TGF-β2 and TGF-β receptors by 1α,25(OH)2D3 might account for the inhibition of human osteoblast growth seen following 1α,25(OH)2D3 treatment.

UR - http://www.scopus.com/inward/record.url?scp=0031590411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031590411&partnerID=8YFLogxK

U2 - 10.1006/bbrc.1997.7544

DO - 10.1006/bbrc.1997.7544

M3 - Article

C2 - 9367838

AN - SCOPUS:0031590411

VL - 239

SP - 734

EP - 739

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -